Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04307199
Other study ID # NUIreland - MILO
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 30, 2020
Est. completion date December 30, 2021

Study information

Verified date May 2020
Source National University of Ireland, Galway, Ireland
Contact Elaine M Finucane, BSc
Phone +353 91 495938
Email Elainemay.finucane@nuigalway.ie
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multicentre, pragmatic, parallel group, pilot randomised controlled trial with an embedded factorial design.


Description:

The primary aim of the MILO study is to inform the optimal design of a future definitive randomised trial to evaluate the effectiveness (including optimal timing and frequency) of membrane sweeping to prevent post-term pregnancy. We will also assess the acceptability and feasibility of the proposed trial interventions to clinicians and women (through focus group interviews).

Methods/Design

Multicentre, pragmatic, parallel group, pilot randomised controlled trial with an embedded factorial design. Pregnant women with a live, singleton fetus ≥ 38 weeks gestation, cephalic presentation, longitudinal lie, intact membranes, English speaking and ≥18 years of age will be randomised in a 2:1 ratio to:

• Membrane sweep versus no membrane sweep

Women allocated randomly to a sweep will then be randomised further (factorial component) to:

- early (from 39 weeks) versus late (from 40 weeks) sweep commencement; and

- a single verses weekly sweep

The proposed feasibility study consists of four work packages i.e., (1) a multicentre, pilot randomised trial, 2) a health economic analysis and 3) a qualitative study (4) a study within the host trial (a SWAT).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 132
Est. completion date December 30, 2021
Est. primary completion date March 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Pregnant women carrying a live singleton fetus = 38 weeks completed gestation.

- (Gestational age will be calculated from the first day of the last menstrual period and an

- ultrasound examination carried out in the 2nd trimester)

- Longitudinal lie

- Cephalic presentation

- Intact amniotic

- = 18 years of age on enrollment

Exclusion Criteria:

- Not able to communicate in english

- contraindications to a vaginal examination

- contraindications to a vaginal birth

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Amniotic membrane sweep
Amniotic membrane sweeping is defined as the manual detachment of the inferior pole of the amniotic membranes from the lower uterine segment. This is performed with consent by a clinician digitally through a circular motion during a vaginal examination. If the cervical os is closed massage of the cervix will be accepted.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
National University of Ireland, Galway, Ireland Health Research Board, Ireland

Outcome

Type Measure Description Time frame Safety issue
Primary Recruitment Evaluation of the number and percentage of eligible women who are recruited and randomised to the study. Assessed by study-specific checklists. Duration of the recruitment process (approximately 8 months )
Primary Retention Evaluation of the number and percentage of eligible women who are randomised, take part in and adhere to the study protocols. Data will be extracted from routinely collected data. At month 15 approximately
Primary Adherence with the trial interventions. Evaluation of adherence with the trial interventions, and reasons for non-compliance assessed by study-specific checklists. Data will be extracted from routinely collected data and focus group interviews with clinicians and participants at six weeks post intervention. At month 15 approximately
Primary Evaluation of the randomisation process. Evaluation of effective allocation of participants to the intervention/control group assessed by study-specific checklists and evaluation of the randomisation protocol throughout the randomisation period. At month 15 approximately
Primary Evaluation of attrition rates Evaluation of attrition rates assessed by study-specific checklists. Data will be extracted from routinely collected data. At month 15 approximately
Primary Evaluation of the types of attrition Evaluation of the types of attrition assessed by case report forms. Data will be extracted from routinely collected data. At month 21 approximately
Primary Evaluation of the data collection process through study specific checklists Evaluated, statistically and narratively, by assessing the completeness of outcome measurements at baseline and postnatal (6 weeks) through study specific checklists. Researchers will manually examine the data collected. They will assess the proportion of complete data collection forms, the quality of data collected and the applicability of this data in facilitating pilot trial outcomes. At month 21 approximately
Primary Estimate the main effect of individual intervention components and their interactions Estimates (with measures of uncertainty) of the main effect of individual intervention components and any interaction effect between the main effects of the embedded factorial design will be assessed and reported using regression analysis. At month 21 approximately
Primary Evaluation of the data analysis process As this is a feasibility study formal hypothesis testing will not be undertaken. Researchers will manually examine the data collected. Evaluation of the data analysis process will be undertaken through the assessment of gaps and limitations to the analysis process measured by study-specific checklist. Findings will be reported through descriptive statistics and graphical summaries. At month 21 approximately
Primary Evaluation of the EQ5D Assessment of the mechanism of, timing of and delivery of the EQ5D through study specific checklists. At month 21 approximately
Primary Feasibility of cost analyses process through analysis of study specific documentation. Assessment of data collection tools to undertake cost effectiveness analysis through study specific documentation. Researchers will manually examine data to assess the mechanism of, timing of and delivery of the cost analysis tools. At month 21 approximately
Primary Feasibility of the cost effectiveness analyses Assessment of the mechanism and utilisation of the incremental cost-effectiveness ratio (ICER), through study specific checklists. At month 21 approximately
Secondary Number of participants achieving a spontaneous onset of labour Labour which begins spontaneously. From time of randomisation to commencement of spontaneous onset of labour or formal induction of labour or caesarean section (up to 5 weeks)
Secondary Number of participants who underwent an induction of labour Formal induction of labour using pharmacological or surgical methods. From time of randomisation to commencement of formal induction of labour (up to 5 weeks).
Secondary Number of participants achieving a spontaneous vaginal birth Spontaneous vaginal birth From time of randomisation to birth of baby (up to 5 weeks)
Secondary Instrumental birth Vaginal birth which is assisted with the use of instruments. From time of randomisation to birth of baby (up to 5 weeks)
Secondary Caesarean Section Birth which is achieved through the surgical procedure caesarean section. From time of randomisation to birth of baby (up to 5 weeks)
Secondary Post-Partum Haemorrhage = 500mls Blood loss = 500mls within the first 24 hours of the birth of a baby From time of birth to 24 hours after the birth of baby.
Secondary Antepartum haemorrhage requiring hospital admission Bleeding from the genital tract, from 24+0 weeks of pregnancy and before the birth of the baby. From 24+0 weeks of pregnancy to birth of baby (up to 18 weeks)
Secondary Uterine hyperstimulation with/without fetal heart rate (FHR) changes Uterine hyperstimulation defined as uterine tachysystole (more than five contractions per ten minutes for at least twenty minutes) and uterine hypersystole/hypertonicity (a contraction lasting at least two minutes). These may or not be associated with changes in the fetal heart rate pattern (persistent decelerations, tachycardia or decreased short term variability. From time of randomisation to birth of baby (up to 5 weeks)
Secondary Serious maternal death or morbidity Serious maternal death or morbidity (e.g. uterine rupture, admission to intensive care unit, septicaemia) From time of randomisation to six weeks postnatal (up to 11 weeks).
Secondary Epidural analgesia Introduction of a local anaesthetic into the epidural space of the vertebral canal. From time of randomisation to birth of baby (up to 5 weeks)
Secondary Augmentation of labour The stimulation of uterine contractions using pharmacologic methods or artificial rupture of membranes to increase their frequency and/or strength following the onset of spontaneous labor or contractions following spontaneous rupture of membranes (ACOG 2014) From commencement of established labour to birth of baby (up to 2 days)
Secondary Pyrexia in labour Pyrexia that developed anytime after onset of labour. From commencement of established labour to birth of baby (up to 2 days)
Secondary Uterine rupture All clinically signi?cant ruptures of unscarred or scarred uteri. Trivial scar dehiscence noted incidentally at the time of surgery will be excluded From time of randomisation to birth of baby (up to 5 weeks)
Secondary EQ5D-5L EuroQol EQ5D-5L survey instrument. From time of randomisation to six weeks postnatal (up to 11 weeks)
Secondary Serious neonatal morbidity e.g. seizures, birth asphyxia defined by trialists, neonatal encephalopathy, disability in childhood, Proven and suspected neonatal sepsis From time of birth of baby to six weeks postnatal.
Secondary Apgar score < 7 at five minutes. The Apgar score provides an accepted and convenient method for reporting the status of the newborn infant immediately after birth and the response to resuscitation if needed (ACOG 2015). From birth of baby to five minutes of life.
Secondary Cord PH < 7.20 Umbilical cord blood gas test. From birth of infant to collection of cord bloods after delivery of the placenta (an average of 15 minutes)
Secondary Neonatal encephalopathy Severity of hypoxic ischaemic encephalopathy assessed using Sarnat staging; i)Stage 1 (mild): hyper-alertness, hyper-reflexia, dilated pupils, tachycardia, absence of seizures; ii)Stage 2 (moderate): lethargy, hyper-reflexia, miosis, bradycardia, seizures, hypotonia with weak suck and Moro reflexes; iii)Stage 3 (severe): stupor, flaccidity, small to mid-position pupils which react poorly to light, decreased stretch reflexes, hypothermia and absent Moro reflex. From time of birth to six weeks postnatal.
Secondary Perinatal death The perinatal period is defined as "commences at 22 completed weeks (154 days) of gestation and ends seven completed days after birth of baby." From time of randomisation to seven completed days after birth of baby (up to 6 weeks)
Secondary Admission to neonatal intensive care unit or equivalent Admission of infant to neonatal intensive care unit or equivalent From time of birth to six weeks postnatal.
Secondary Length of time from membrane sweep to birth of baby. Length of time from membrane sweep to birth of baby . From time of membrane sweep to birth of baby (up to 4 weeks)
Secondary Length of time from formal induction of labour to birth of baby. Length of time from formal induction of labour to birth of baby. From time of formal induction of labour to birth of baby (up to 2 weeks)
Secondary Overall length of maternal hospital stay Overall length of maternal hospital stay From time of randomisation to six weeks postnatal (up to 11 weeks).
Secondary Length of infant stay in neonatal intensive care unit or equivalent Length of infant stay in neonatal intensive care unit or equivalent From time of birth to six weeks postnatal.
See also
  Status Clinical Trial Phase
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Completed NCT03284515 - Vaccination In Pregnancy Gene Signature: VIP Signature Study
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Enrolling by invitation NCT04527926 - STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy N/A
Recruiting NCT04278651 - Early Antenatal Support for Iron Deficiency Anemia Phase 4
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT06258902 - Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
Completed NCT05487196 - Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia Phase 2
Completed NCT03750968 - Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects Phase 2
Enrolling by invitation NCT06127277 - Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care N/A
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT06069856 - Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06069869 - Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial Phase 3
Not yet recruiting NCT06079918 - Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania Phase 3
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A